GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Regeneron Pharmaceuticals, Inc. (REGN) [hlAlert]

Rating:
Overweight
REGN
up 3,694.07 %

Regeneron Pharmaceuticals, Inc. (REGN) rated Overweight by Piper Jaffray

Posted on: Monday,  Jul 1, 2013  8:25 AM ET by Piper Jaffray

Piper Jaffray rated Overweight Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on 07/01/2013. Previously Piper Jaffray rated Buy Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on
03/30/2009., when the stock price was $14.18. Since then, Regeneron Pharmaceuticals, Inc. has gained 3694.08% as of 01/27/2016's recent price of $538.00.
If you would have followed the previous Piper Jaffray's recommendation on REGN, you would have gained 3694.07% of your investment in 2494 days.

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)

At Piper Jaffray, we understand there’s no substitute for relevant and timely research. That's why we provide: * fundamental and technical research * value-added investment ideas * market analysis With the information our research team provides, you’ll make better and more informed decisions for your portfolio.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/1/2013 8:25 AM Buy
None
232.98
as of 12/13/2013
1 Week down  -4.65 %
1 Month down  -2.74 %
3 Months down  -7.02 %
1 YTD up  57.59 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/30/2009 8:25 AM Buy
None
14.18

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy